Researchers have found that lowering the the levels of a protein called sarcolipin lessens muscle weakness and improves skeletal and…
Articles by Patricia Inácio, PhD
Solid Biosciences announced the pending start of a first clinical trial to test the company’s leading investigational therapy – called…
The U.S. Food and Drug Administration has taken a step that will allow Sarepta Therapeutics to start clinical trials of…
Respiratory activity is significantly impaired in Duchenne muscular dystrophy (DMD), but a new mouse study suggests that enhancing breathing via…
The newly approved Duchenne muscular dystrophy therapy Exondys 51 (eteplirsen) stays in immune cells several days after leaving the blood, continuing…
The biotechnology company Capricor Therapeutics recently presented data that support the use of its peripheral intravenous delivery method in the…
Capricor Therapeutics recently shared an update of the company’s quarterly financial results and operational highlights, including positive results…
The investigational therapy MA-0211, also called MTB-1, a potential treatment for Duchenne Muscular Dystrophy (DMD), was approved for a Phase…
A comprehensive 12-year genetic and clinical analysis of unrelated patients with congenital muscular dystrophies (CMDs) in the U.K. has confirmed…
Overnight use of hand braces preserves hand function and delays the development of shortened muscles or joints in boys who…